Drugs / Engineered immune effector cells (EIE)
Engineered immune effector cells (EIE)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03535246 | Jul 2025 → Jun 2028 expected | cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Engineered immune effector cells (EIE) | “Engineered immune effector cells (EIE)” NCT03535246 ↗ |
| Modality | Cell therapy | “ex vivo manipulated EIE cells including chimeric antigen receptor (CAR) modified immune cells” NCT03535246 ↗ |
| Route | Intravenous | “by intravenous and intratumoral injection” NCT03535246 ↗ |
| Route | Other | “by intravenous and intratumoral injection” NCT03535246 ↗ |